Bril V, Benatar M, Andersen H, Vissing J, et al. Efficacy and safety of rozanolixizumab in moderate-to-severe generalised myasthenia gravis: A phase 2 RCT. Neurology 2020 Nov 20. pii: WNL.0000000000011108.
PMID: 33219142